Tarsier Pharma Ltd. (TARX) — IPO Dossier

A late-stage eye-drug developer takes a second swing at a Phase 3 that already missed — funded by an offering the company itself says won’t be enough to finish the job.

Demand read

BDI on TARX reads ACTIVE at the READY stage — a middle-of-the-band demand read built from a below-midpoint Pricing Signal, a Tier-3 underwriter score, a moderate biotech Sector Momentum, and the live Market Regime. The score freezes at pricing (expected the evening of July 9) under the standard book-built methodology, and is graded thereafter on offer→open. BDI measures observable demand conditions around the offering — it is not a prediction of trial outcomes, clinical success, or share performance, and nothing in this dossier is investment advice.

The Bellipo take

Read this one with your eyes open. Tarsier is a clinical-stage ophthalmology company with a genuinely interesting immunomodulator platform and a lead drug, TRS01, for a real unmet need — non-infectious anterior uveitis. But the filing is unusually candid about the hard parts, and so are we: the prior Phase 3 trial missed its primary endpoint (zero anterior-chamber-cell clearance advantage), the auditor’s report carries an explicit going-concern paragraph, and the company held about $2.0 million in cash at year-end. The new pivotal trial runs under an FDA Special Protocol Assessment — a real de-risking step — but the ~$41 million net raise doesn’t fund the finish line: management estimates $65–85 million to commercialize TRS01, so more dilution is a when, not an if. Add a sole Tier-3 bookrunner taking 3.5% warrants, a 10-for-1 forward split just before close, and IPO proceeds repaying a CEO loan, and you have a high-risk, binary micro-cap. That’s not a verdict on the science — it’s the structure the filing itself describes. If you’re reading Bellipo before buying this, you’re doing exactly the right thing.